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INTRODUCTION
As the need for less invasive therapy increases, 
percutaneous endovascular procedures are increasingly 
performed as an alternative to surgery. The common 
femoral artery is the mainstay for arterial access used 
for endovascular procedures, as the common femoral 
artery allows reliable and easy access in most cases, with 
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reasonably consistent hemostasis after the procedure. 
Although manual compression has classically been the 
principal method for achieving hemostasis for femoral 
arteriotomy sites, manual compression increases personnel 
demands and necessitates prolonged bed rest and 
patient discomfort. To overcome the disadvantages of 
manual compression, arterial closure devices (ACDs) have 
been developed and are increasingly used for achieving 
hemostasis in arteriotomy sites. Currently, most of the 
commonly used ACDs are either collagen plug-type or 
suture-mediated devices (1). However, the safety of ACDs 
remains in question and they may increase the risks of 
infection and leg ischemia because most ACDs place foreign 
bodies inside the artery and tissue track (2-7). Moreover, 
there are concerns that ACDs may increase the risk of 
hematomas and pseudoaneurysm formation compared with 
standard manual compression (8, 9).
A pneumatic compression device is an external compression 
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device which usually involves a small inflatable balloon or 
bulb, and compression to the femoral arteriotomy occurs 
via the pressure exerted by the inflated balloon (10-13). 
Presumably, the use of a pneumatic compression device is 
not associated with an increased risk of infection or leg 
ischemia given that nothing is left inside the artery or 
tissue track. However, there is a relative paucity of research 
on this type of device compared with the extensive body of 
information on collagen plug-type or suture-mediated devices.
The purpose of this study was to report our initial 
experience on the technical feasibility and safety of a 
new pneumatic compression device (GH-150; Kyung-Won 
Medical, Seoul, Korea).
MATERIALS AND METHODS
Patients
Our Institutional Review Board did not require approval of 
patients or patient informed consent for this retrospective 
study and included 40 consecutive patients in whom 
hemostasis of femoral arteriotomy sites was achieved 
using the GH-150 device over a 6-month period between 
October 2009 and April 2010 at our cancer center. All 
patients underwent transarterial chemoembolization for 
the treatment of hepatocellular carcinoma (n = 39) or 
transarterial embolization for the control of bleeding which 
occurred after radiofrequency ablation of an intrahepatic 
metastatic lesion resulting from rectal cancer (n = 1). An 
international normalized ratio (INR) < 1.5 and a platelet 
count > 50,000/ µl were required to perform a percutaneous 
arteriotomy according to our protocol. The patient 
characteristics and interventional procedural details are 
summarized in Table 1. The exclusion criteria for application 
of the device included severe peripheral vascular disease, 
marked obesity, an arterial sheath > 7 Fr, and patients who 
declined to provide informed consent for the use of the 
device. Fifteen patients had a prolonged prothrombin time 
(INR > 1.2) and/or four patients received transfusions of 
platelet concentrates to maintain platelet counts > 50,000/µl.
 
Device and Hemostasis Procedure
The GH-150 is a single-use, disposable device and consists 
of a cruciform main body and four pieces of supplementary 
tape. The main body has a self-adhesive peel backing and 
a semi-compliant inflatable bulb (4 cm in diameter) under 
a transparent plastic dome at the center of the body and 
supplementary tapes also have a self-adhesive peel backing.
In brief, hemostasis was achieved as follows: With the 
sheath in the femoral artery, the main body was secured 
over the puncture site after removal of the self-adhesive 
backing while positioning the center of the bulb 1 cm 
proximal to the sheath entry site. Supplementary tapes were 
applied over the wings of the main body to reinforce the 
attachment of the main body to the skin (Fig. 1). Then, the 
bulb was inflated with room air (approximately 150 ml in 
volume) and the sheath was removed while keeping manual 
compression over the bulb. Then, manual compression 
was gradually released over a few seconds under visual 
inspection for any bleeding below the plastic dome. If any 
signs of bleeding were present, the bulb was inflated with 
an additional 20-30 cc of room air. The device was applied 
for a set time of 10 minutes, which was the routine set 
time for manual compression at our institution. When any 
signs or symptoms of leg ischemia developed during the 
set time of the device application, the bulb was slowly 
deflated until the ischemic signs or symptoms disappeared, 
while maintaining control of bleeding. After 10 minutes, 
the device was deflated and hemostasis was confirmed by 
viewing the puncture site through the deflated bulb. If 
hemostasis was successful, the bulb was lightly re-inflated 
with 70-80 ml of room air and the patient was returned to 
Table 1. Patient Characteristics
N 40
Male/Female 32/8
Age (years) 58.4 ± 11.1
Weight (kg) 64.2 ± 11.2
Body mass index (BMI, kg/m
2)
18.5 </18.5-24.9/25-29.9/≥ 30 3/22/13/2
Liver disease
HBV/HCV/ Alcoholic/NBNC 28/6/4/1
Liver cirrhosis 33
Diabetes 6 (15%)
Hypertension 11 (28%)
Sheath size
5 Fr/6 Fr 35/5
Procedure time with sheath in situ (min) 35.1 ± 16.8
Platelet count before the procedure (10
3/µl) 114 ± 61
< 50 4 (10%)
Prothrombin time (INR) 1.19 ± 0.12
> 1.2 15 (38%)
Note.— Numbers are expressed as mean ± SD or number of 
patients (percentage). HBV = hepatitis B virus, HCV = hepatitis 
C virus, INR = international normalized ratio, NBNC = non-B 
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the ward with the device kept in place. After 4 hours of 
bed rest, the device was finally removed and the groin was 
checked for any bleeding or hematoma formation before 
ambulation. Pulsation of the ipsilateral dorsalis pedis was 
checked every 30 minutes for two hours and then hourly 
until the device was removed.
Assessment
We reviewed medical records for the outcomes and 
complications of hemostasis. Technical success was 
defined as achieving immediate hemostasis after the 
10-minute application of the device without the need for 
additional manual compression or other means of achieving 
hemostasis. Clinical success was defined as a patient having 
technical success and could ambulate after four hours of 
bed rest without any complications related to hemostasis. 
Complications were classified according to the Society 
of Interventional Radiology guidelines (14). A major 
complication was any event that resulted in additional 
therapy, including an increased level of care, hospital stay 
beyond observation status, permanent adverse sequelae, 
and death. Included in the category of major complications 
is transfusion of blood products or additional interventions 
such as percutaneous drainage or endovascular procedures 
or surgery. All other complications were classified as minor.
RESULTS
Achieving hemostasis using the GH-150 was tolerable in 
all patients with minimal groin pain or discomfort despite 
the prolonged device application. No patients complained of 
any ischemic signs or symptoms during device application, 
although the ipsilateral dorsalis pedis was weakly palpable 
during the 10-minute high-volume (150 ml) application (Fig. 
2). Technical success was achieved in 38 patients (95%). In 
two patients, persistent oozing of blood was noted despite 
additional inflation of the bulb; eventually, hemostasis 
was achieved by manual compression. Both the technical 
failures had an INR < 1.5 and a platelet count > 50,000/ 
µl, and their body mass indices were 24.53 and 25.96, 
respectively. The arteriotomy sites of the technical failures 
were just above the inguinal crease, which were the routine 
arteriotomy sites at our institution. Additional inflation was 
not necessary in other patients. 
Upon removal of the lightly-applied device after four 
hours, minimal oozing was noted in another patient, 
which was successfully controlled by the simple placement 
of a sand bag for 20 minutes. The remaining 37 patients 
were able to initiate ambulation according to the 
protocol without the need for any additional measures 
(clinical success, 93%). No patients experienced any late 
complications regarding hemostasis during an average 
follow-up period of 238 days (range, 26-407 days). Twenty 
six patients underwent a successful re-arteriotomy of the 
ipsilateral femoral artery for an average of 155 days (range, 
24-377 days) after the initial use of the GH-150.
DISCUSSION
Previous reports on the use of pneumatic compression 
devices are relatively limited compared with other ACDs, 
and have been focused on use during coronary intervention 
procedures (10-13). Currently, two types of pneumatic 
compression devices are available (Femostop; RADI Medical 
System, Uppsala, Sweden and Safeguard; Datascope, 
Fig. 1. GH-150 applied to model doll. Supplementary tapes 
(arrows) are applied over wings of main body.
Fig. 2. Non-enhanced CT scan of 63-year-old male patient. 
Femoral artery (arrows) is firmly compressed by inflated GH-150 
(arrowheads) which is considered to lead to weak pulsation of 
ipsilateral dorsalis pedis.Korean J Radiol 13(1), Jan/Feb 2012 kjronline.org 64
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Fairfield, NJ). The Safeguard is structurally similar to 
the GH-150, except that it has a smaller bulb and no 
supplementary tapes. The key difference between the GH-
150 and the Safeguard is that the Safeguard is aimed to 
assist manual compression, not to substitute for manual 
compression as does the GH-150. The Femostop is used 
to substitute manual compression like the GH-150. The 
Femostop consists of a large plastic arch bar positioned 
over the groin and a belt positioned under the patient’s 
hips to hold the plastic bar. Because the plastic arch and 
the belt are intended to be reused, a switch to a pressure 
dressing is necessary to maintain hemostasis and to assist 
in reducing hematoma formation when the patient returns 
to the ward (15). In contrast, the GH-150 is a single use 
device in its entirety and an additional pressure dressing is 
not necessary because it is being kept in place and exerts 
pressure to maintain hemostasis for the entire duration of 
the compression.
Successful hemostasis rates of ACDs are reportedly to be 
as high as 95% in experienced hands (1, 16). However, each 
and every ACD has its own learning curve depending on the 
complexity of device deployment. Failure rates have been 
reported to be approximately 15% during early experience 
(17-19). Though a direct comparison with previous studies 
may be difficult due to different patient selection, it is 
noteworthy that the clinical success rate of this study was 
93% (37 of 40). The two cases of technical failure in the 
current study occurred during the early period and another 
clinical failure involved minimal oozing of blood which 
was easily controlled by placing a sand bag. The technical 
failures were likely to be a result of the lack of experience 
because their coagulation profiles were tolerable and 
they were not obese. Appropriate adjustment of the bulb 
position such that the bulb fits into the groin and exerts 
maximal pressure on the arteriotomy site may be of greater 
importance than additional inflation of the bulb. 
Given that oncologic procedures may be performed 
repeatedly in a single patient, the issue of re-puncture and 
repeated use of ACDs in a femoral artery is important (1). 
However, little is known about the result of the repeated 
use of ACDs in a femoral artery, and that the repeated use 
of ACDs may result in the formation of granulomas around 
the femoral artery induced by foreign bodies incorporated 
in ACDs is a valid concern. Pneumatic compression devices 
appear to be appropriate for use when repeated punctures 
are expected, because there are no foreign bodies involved. 
In the current study, approximately two-thirds of patients 
underwent re-puncture of the ipsilateral femoral artery 
as early as 24 days after the use of the GH-150 and no 
abnormalities were found, which may disturb the re-
puncture.
It seems intuitive that the use of any ACDs is associated 
with increased cost and another advantage of the GH-150 
over collagen plug-type or suture-mediated ACDs may be its 
lower cost ($80 versus $150-200) (20). However, whether 
the utilization of ACDs is cost effective depends on a variety 
factors including the frequency of vascular complications, 
the impact of the use of ACDs for the complication rate, and 
the potential for ACDs to substantially alter post-procedure 
management patterns. A comprehensive cost-benefit 
analysis of the GH-150 vs. manual compression or the GH-
150 versus other ACDs is needed to determine the cost-
effectiveness of the device use.
One of the advantages that support the use of ACDs is 
that collagen plug-type or suture-mediated ACDs may permit 
early ambulation, even in fully anti-coagulated patients 
because these types of ACDs provide active approximation 
of the arteriotomy sites (16, 17, 19, 21). For this reason, 
pneumatic compression devices which do not provide active 
approximation are not recommended in the clinical setting 
of intensive anticoagulation due to prolonged compression 
times (13). The liver plays a central role in the maintenance 
of hemostasis. Liver diseases, such as viral hepatitis or 
liver cirrhosis, are associated with a variety of hemostatic 
abnormalities by disturbing the synthesis of proteins 
required for hemostasis and affecting platelet count and 
function (22). In the current study, a substantial portion 
(16 of 40) of the patients had prolonged prothrombin times 
and/or necessitated transfusions of platelet concentrates 
due to underlying liver diseases. However, hemostasis 
was successfully achieved in all of these patients. Further 
studies are needed to verify the usefulness of the GH-150 in 
a therapeutic setting of anti-coagulation or in patients who 
have moderate or severe hemostatic abnormalities.
This study had a few limitations. First, the study was 
restricted to patients who underwent oncologic procedures. 
Therefore, our results cannot be directly extrapolated to 
coronary or peripheral interventions and further analyses are 
needed to fully assess the outcomes of subsets not included 
in the present study. Second, due to its retrospective 
design, the current study lacks ultrasound examinations to 
evaluate the complications associated with the arteriotomy 
and use of the GH-150. The prolonged application of the 
GH-150 might compromise the venous drainage, which Korean J Radiol 13(1), Jan/Feb 2012 kjronline.org 65
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may also be evaluated by ultrasound examinations. Third, 
although we applied the GH-150 with a set inflation volume 
and time to develop a standardized protocol for use, use 
of the GH-150 needs to be customized according to the 
clinical situation and patient characteristics in practice.
Our data suggest that the GH-150 is an easy-to-use 
device with a short learning curve which provides reliable 
hemostasis of the femoral arteriotomy sites in patients 
who undergo transarterial chemoembolization or bland 
embolization without other hemostasis measures. 
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